State of the art of B-type natriuretic peptide (BNP) immunoassays. Recent studies have demonstrated that the precursor of BNP (proBNP) constitutes the major part of BNP-related peptides detectable in plasma of patients with heart failure by the commercially available immunoassays considered specific for the BNP hormone. Since proBNP significantly cross-reacts with commercial immunoassays for BNP, manufacturers should test and clearly declare the cross-reaction with proBNP in their BNP methods. Owing to the differences in cross-reaction with proBNP as well as in specificity, respectively, for the NH2- or COOH-terminal part of the peptide hormone chain, BNP immunoassays show significant between-method differences. Immunoassays for NT-proBNP, which all use standard materials and antibodies provided by the same company, show lower differences (generally <20%). Clinicians should take into account these differences among methods when they compare results obtained from different laboratories, which use different BNP immunoassays. Accordingly, the use of a common decisional limit for all BNP immunoassay methods, as suggested by the most recent international guidelines, may be unreliable.

Stato dell'arte dell'immunodosaggio dei peptidi natriuretici di tipo B

FRANZINI, MARIA;CLERICO, ALDO
2015-01-01

Abstract

State of the art of B-type natriuretic peptide (BNP) immunoassays. Recent studies have demonstrated that the precursor of BNP (proBNP) constitutes the major part of BNP-related peptides detectable in plasma of patients with heart failure by the commercially available immunoassays considered specific for the BNP hormone. Since proBNP significantly cross-reacts with commercial immunoassays for BNP, manufacturers should test and clearly declare the cross-reaction with proBNP in their BNP methods. Owing to the differences in cross-reaction with proBNP as well as in specificity, respectively, for the NH2- or COOH-terminal part of the peptide hormone chain, BNP immunoassays show significant between-method differences. Immunoassays for NT-proBNP, which all use standard materials and antibodies provided by the same company, show lower differences (generally <20%). Clinicians should take into account these differences among methods when they compare results obtained from different laboratories, which use different BNP immunoassays. Accordingly, the use of a common decisional limit for all BNP immunoassay methods, as suggested by the most recent international guidelines, may be unreliable.
2015
Prontera, Concetta; Franzini, Maria; Masotti, Silvia; Giovannini, Stefania; Zucchelli, Gian Carlo; Clerico, Aldo
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/771439
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact